Pharmacological management of hyponatremia

References

• Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006;119:S30–S35.
   PubMed Web of Science ®Google Scholar
• Ayus JC, Wheeler JM, Arieff AI. Postoperative hyponatremic encephalopathy in menstruant women. Ann Intern Med. 1992;117:891–897.
   PubMed Web of Science ®Google Scholar
• Ayus JC, Achinger SG, Arieff A. Brain cell volume regulation in hyponatremia: role of sex, age, vasopressin, and hypoxia. Am J Physiol Renal Physiol. 2008;295:F619–F624.
   PubMed Web of Science ®Google Scholar
• Ayus JC, Varon J, Arieff AI. Hyponatremia, cerebral edema, and noncardiogenic pulmonary edema in marathon runners. Ann Intern Med. 2000;132:711–714.
   PubMed Web of Science ®Google Scholar
• Ayus JC, Arieff AI. Pulmonary complications of hyponatremic encephalopathy. Noncardiogenic pulmonary edema and hypercapnic respiratory failure. Chest. 1995;107:517–521.
   PubMed Web of Science ®Google Scholar
• Vexler ZS, Ayus JC, Roberts TP, et al. Hypoxic and ischemic hypoxia exacerbate brain injury associated with metabolic encephalopathy in laboratory animals. J Clin Invest. 1994;93:256–264.
   PubMed Web of Science ®Google Scholar
• Ayus JC, Armstrong D, Arieff AI. Hyponatremia with hypoxia: effects on brain adaptation, perfusion, and histology in rodents. Kidney Int. 2006;69:1319–1325.
   PubMed Web of Science ®Google Scholar
• Ayus JC, Krothapalli RK, Arieff AI. Treatment of symptomatic hyponatremia and its relation to brain damage. A prospective study. N Engl J Med. 1987;317:1190–1195.
   PubMed Web of Science ®Google Scholar
• Greenberg A, Verbalis JG, Amin AN, et al. Current treatment practice and outcomes. Report of the hyponatremia registry. Kidney Int. 2015;88:167–177.
   PubMed Web of Science ®Google Scholar
• Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126:S1–S42.
   PubMed Web of Science ®Google Scholar
• Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol. 2014;170:G1–G47.
   PubMed Web of Science ®Google Scholar
• Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342:1581–1589.
   PubMed Web of Science ®Google Scholar
• Ayus JC, Arieff A, Moritz ML. Hyponatremia in marathon runners. N Engl J Med. 2005;353:427–428. author reply 27–8.
   PubMed Web of Science ®Google Scholar
• Ayus JC, Caputo D, Bazerque F, et al. Treatment of hyponatremic encephalopathy with a 3% sodium chloride protocol: a case series. Am J Kidney Dis. 2015;65:435–442.
   PubMed Web of Science ®Google Scholar
• Moritz ML, Ayus JC. 100 cc 3% sodium chloride bolus: a novel treatment for hyponatremic encephalopathy. Metab Brain Dis. 2010;25:91–96.
   PubMed Web of Science ®Google Scholar
• Sood L, Sterns RH, Hix JK, et al. Hypertonic saline and desmopressin: a simple strategy for safe correction of severe hyponatremia. Am J Kidney Dis. 2013;61:571–578.
   PubMed Web of Science ®Google Scholar
• Ayus JC, Arieff AI. Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and mortality. JAMA. 1999;281:2299–2304.
   PubMed Web of Science ®Google Scholar
• Arieff AI, Ayus JC, Fraser CL. Hyponatraemia and death or permanent brain damage in healthy children. BMJ. 1992;304:1218–1222.
   PubMed Web of Science ®Google Scholar
• Achinger SG, Arieff AI, Kalantar-Zadeh K, et al. Desmopressin acetate (DDAVP)-associated hyponatremia and brain damage: a case series. Nephrol Dial Transplant. 2014;29:2310–2315.
   PubMed Web of Science ®Google Scholar
• Ayus JC, Olivero JJ, Frommer JP. Rapid correction of severe hyponatremia with intravenous hypertonic saline solution. Am J Med. 1982;72:43–48.
   PubMed Web of Science ®Google Scholar
• Arieff AI, Ayus JC. Endometrial ablation complicated by fatal hyponatremic encephalopathy. JAMA. 1993;270:1230–1232.
   PubMed Web of Science ®Google Scholar
• Ayus JC, Arieff AI. Glycine-induced hypo-osmolar hyponatremia. Arch Intern Med. 1997;157:223–226.
   PubMedGoogle Scholar
• Mohmand HK, Issa D, Ahmad Z, et al. Hypertonic saline for hyponatremia: risk of inadvertent overcorrection. Clin J Am Soc Nephrol. 2007;2:1110–1117.
   PubMed Web of Science ®Google Scholar
• Burst V, Grundmann F, Kubacki T, et al. Thiazide-associated hyponatremia, report of the hyponatremia registry: an observational multicenter international study. Am J Nephrol. 2017;45:420–430.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Liamis G, Elisaf MS. Ten pitfalls in the proper management of patients with hyponatremia. Postgrad Med. 2016;128:516–522.
   PubMed Web of Science ®Google Scholar
• Musch W, Decaux G. Treating the syndrome of inappropriate ADH secretion with isotonic saline. QJM. 1998;91:749–753.
   PubMed Web of Science ®Google Scholar
• Furst H, Hallows KR, Post J, et al. The urine/plasma electrolyte ratio: a predictive guide to water restriction. Am J Med Sci. 2000;319:240–244.
   PubMed Web of Science ®Google Scholar
• Winzeler B, Lengsfeld S, Nigro N, et al. Predictors of nonresponse to fluid restriction in hyponatraemia due to the syndrome of inappropriate antidiuresis. J Intern Med. 2016;280:609–617.
   PubMed Web of Science ®Google Scholar
• Zietse R, van der Lubbe N, Hoorn EJ. Current and future treatment options in SIADH. NDT Plus. 2009;2:iii12–iii19.
   PubMedGoogle Scholar
• Decaux G, Brimioulle S, Genette F, et al. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea. Am J Med. 1980;69:99–106.
   PubMed Web of Science ®Google Scholar
• Decaux G, Soupart A. Urea treatment for exercise-associated hyponatremia. Clin J Sport Med. 2006;16:276. author reply 76.
   PubMed Web of Science ®Google Scholar
• Decaux G, Andres C, Gankam KF, et al. Treatment of euvolemic hyponatremia in the intensive care unit by urea. Crit Care. 2010;14:R184.
   PubMed Web of Science ®Google Scholar
• Cauchie P, Vincken W, Decaux G. Urea treatment for water retention in hyponatremic congestive heart failure. Int J Cardiol. 1987;17:102–104.
   PubMed Web of Science ®Google Scholar
• Verhoeven A, Musch W, Decaux G. Treatment of the polydipsia-hyponatremia syndrome with urea. J Clin Psychiatry. 2005;66:1372–1375.
   PubMed Web of Science ®Google Scholar
• Decaux G, Unger J, Brimioulle S, et al. Hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. Rapid correction with urea, sodium chloride, and water restriction therapy. JAMA. 1982;247:471–474.
   PubMed Web of Science ®Google Scholar
• Decaux G, Mols P, Cauchie P, et al. Treatment of hyponatremic cirrhosis with ascites resistant to diuretics by urea. Nephron. 1986;44:337–343.
   PubMed Web of Science ®Google Scholar
• Sterns RH, Silver SM, Hix JK. Urea for hyponatremia? Kidney Int. 2015;87:268–270.
   PubMed Web of Science ®Google Scholar
• Silver SM, Sterns RH, Halperin ML. Brain swelling after dialysis: old urea or new osmoles? Am J Kidney Dis. 1996;28:1–13.
   PubMed Web of Science ®Google Scholar
• Gankam Kengne F, Nicaise C, Soupart A, et al. Astrocytes are an early target in osmotic demyelination syndrome. J Am Soc Nephrol. 2011;22:1834–1845.
   PubMed Web of Science ®Google Scholar
• Gankam Kengne F, Couturier BS, Soupart A, et al. Urea minimizes brain complications following rapid correction of chronic hyponatremia compared with vasopressin antagonist or hypertonic saline. Kidney Int. 2015;87:323–331.
   PubMed Web of Science ®Google Scholar
• Oo TN, Smith CL, Swan SK. Does uremia protect against the demyelination associated with correction of hyponatremia during hemodialysis? A case report and literature review. Semin Dial. 2003;16:68–71.
   PubMed Web of Science ®Google Scholar
• Soupart A, Coffernils M, Couturier B, et al. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH. Clin J Am Soc Nephrol. 2012;7:742–747.
   PubMed Web of Science ®Google Scholar
• Decaux G, Gankam Kengne F, Couturier B, et al. Mild water restriction with or without urea for the longterm treatment of syndrome of inappropriate antidiuretic hormone secretion (SIADH): can urine osmolality help the choice? Eur J Intern Med. 2018;48:89–93.
   PubMed Web of Science ®Google Scholar
• Vandergheynst F, Brachet C, Heinrichs C, et al. Long-term treatment of hyponatremic patients with nephrogenic syndrome of inappropriate antidiuresis: personal experience and review of published case reports. Nephron Clin Pract. 2012;120:c168–c172.
   PubMedGoogle Scholar
• Hoorn EJ, Zietse R. Diagnosis and treatment of hyponatremia: compilation of the guidelines. J Am Soc Nephrol. 2017;28:1340–1349.
   PubMed Web of Science ®Google Scholar
• Thibonnier M, Conarty DM, Preston JA, et al. Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol. 1998;449:251–276.
   PubMed Web of Science ®Google Scholar
• Xu DL, Martin PY, Ohara M, et al. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Invest. 1997;99:1500–1505.
   PubMed Web of Science ®Google Scholar
• Kwon TH, Hager H, Nejsum LN, et al. Physiology and pathophysiology of renal aquaporins. Semin Nephrol. 2001;21:231–238.
   PubMed Web of Science ®Google Scholar
• Fushimi K, Uchida S, Hara Y, et al. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature. 1993;361:549–552.
   PubMed Web of Science ®Google Scholar
• Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int. 2006;69:2124–2130.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Questions and answers on the withdrawal of the marketing application for aquilda: EMEA/277960/2008. [cited 2018 Apr 3]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2010/01/WC500066191.pdf
   Google Scholar
• Liamis G, Filippatos TD, Elisaf MS. Treatment of hyponatremia: the role of lixivaptan. Expert Rev Clin Pharmacol. 2014;7:431–441.
   PubMed Web of Science ®Google Scholar
• Petereit C, Zaba O, Teber I, et al. A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan. BMC Pulm Med. 2013;13:55.
   PubMed Web of Science ®Google Scholar
• Konstam MA, Gheorghiade M, Burnett JC Jr., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297:1319–1331.
   PubMed Web of Science ®Google Scholar
• Yan L, Xie F, Lu J, et al. The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials. BMC Gastroenterol. 2015;15:65.
   PubMed Web of Science ®Google Scholar
• Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–2112.
   PubMed Web of Science ®Google Scholar
• Verbalis JG, Ellison H, Hobart M, et al. Tolvaptan and neurocognitive function in mild to moderate chronic hyponatremia: a randomized trial (INSIGHT). Am J Kidney Dis. 2016;67:893–901.
   PubMed Web of Science ®Google Scholar
• Bhandari S, Peri A, Cranston I, et al. A systematic review of known interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia and a meta-analysis of the vaptans. Clin Endocrinol. 2017;86:761–771.
   PubMed Web of Science ®Google Scholar
• Lee MY, Kang HJ, Park SY, et al. Cost-effectiveness of tolvaptan for euvolemic or hypervolemic hyponatremia. Clin Ther. 2014;36:1183–1194.
   PubMed Web of Science ®Google Scholar
• Jamookeeah C, Robinson P, O’Reilly K, et al. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden. BMC Endocr Disord. 2016;16:22.
   PubMed Web of Science ®Google Scholar
• Harbeck B, Lindner U, Haas CS. Low-dose tolvaptan for the treatment of hyponatremia in the syndrome of inappropriate ADH secretion (SIADH). Endocrine. 2016;53:872–873.
   PubMed Web of Science ®Google Scholar
• Lenci I, Milana M, Angelico M, et al. Short-term, low-dose use of tolvaptan as a bridge therapy to expedite liver transplant for severe hyponatremic, cirrhotic patients with high model for end-stage liver disease scores. Exp Clin Transplant. 2017;15:689–692.
   PubMed Web of Science ®Google Scholar
• Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407–2418.
   PubMed Web of Science ®Google Scholar
• Samsca package insert. [cited 2018 Apr 4]. Available from: https://www.google.gr/url?sa=t&rct=j&q=&esrc=s&source=web&cd=6&cad=rja&uact=8&ved=0ahUKEwilyK6oz6faAhUBa1AKHUi1D8YQFghVMAU&url=https%3A%2F%2Fmedlibrary.org%2Flib%2Frx%2Fmeds%2Fsamsca%2F&usg=AOvVaw0MVwQiSguwJAYT0GqgUeUK
   Google Scholar
• Pose E, Sola E, Piano S, et al. Limited efficacy of tolvaptan in patients with cirrhosis and severe hyponatremia: real-life experience. Am J Med. 2017;130:372–375.
   PubMed Web of Science ®Google Scholar
• Komiyama Y, Kurosaki M, Nakanishi H, et al. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio. PLoS One. 2017;12:e0174649.
   PubMed Web of Science ®Google Scholar
• Lehrich RW, Greenberg A. Hyponatremia and the use of vasopressin receptor antagonists in critically ill patients. J Intensive Care Med. 2012;27:207–218.
   PubMedGoogle Scholar
• Li-Ng M, Verbalis JG. Conivaptan: evidence supporting its therapeutic use in hyponatremia. Core Evid. 2010;4:83–92.
   PubMedGoogle Scholar
• Tzoulis P, Waung JA, Bagkeris E, et al. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion. Clin Endocrinol. 2016;84:620–626.
   PubMed Web of Science ®Google Scholar
• Der-Nigoghossian C, Lesch C, Berger K. Effectiveness and tolerability of conivaptan and tolvaptan for the treatment of hyponatremia in neurocritically Ill patients. Pharmacotherapy. 2017;37:528–534.
   PubMed Web of Science ®Google Scholar
• Rondon-Berrios H, Berl T. Vasopressin receptor antagonists in hyponatremia: uses and misuses. Front Med. 2017;4:141.
   Web of Science ®Google Scholar
• Zerbe R, Stropes L, Robertson G. Vasopressin function in the syndrome of inappropriate antidiuresis. Annu Rev Med. 1980;31:315–327.
   PubMed Web of Science ®Google Scholar
• Morin D, Tenenbaum J, Ranchin B, et al. Nephrogenic syndrome of inappropriate antidiuresis. Int J Pediatr. 2012;2012:937175.
   PubMedGoogle Scholar
• Schrier RW, Lehman D, Zacherle B, et al. Effect of furosemide on free water excretion in edematous patients with hyponatremia. Kidney Int. 1973;3:30–34.
   PubMed Web of Science ®Google Scholar
• Lapsia V, Kazory A. Loop diuretics for heart failure-associated hyponatremia. Am J Med. 2010;123:e5–e6.
   PubMed Web of Science ®Google Scholar
• Liamis G, Filippatos TD, Liontos A, et al. Hyponatremia in patients with liver diseases: not just a cirrhosis-induced hemodynamic compromise. Hepatol Int. 2016;10:762–772.
   PubMed Web of Science ®Google Scholar
• De Troyer A. Demeclocycline. Treatment for syndrome of inappropriate antidiuretic hormone secretion. JAMA. 1977;237:2723–2726.
   PubMed Web of Science ®Google Scholar
• Kortenoeven ML, Sinke AP, Hadrup N, et al. Demeclocycline attenuates hyponatremia by reducing aquaporin-2 expression in the renal inner medulla. Am J Physiol Renal Physiol. 2013;305:F1705–F1718.
   PubMed Web of Science ®Google Scholar
• Miell J, Dhanjal P, Jamookeeah C. Evidence for the use of demeclocycline in the treatment of hyponatraemia secondary to SIADH: a systematic review. Int J Clin Pract. 2015;69:1396–1417.
   PubMed Web of Science ®Google Scholar
• Perks WH, Walters EH, Tams IP, et al. Demeclocycline in the treatment of the syndrome of inappropriate secretion of antidiuretic hormone. Thorax. 1979;34:324–327.
   PubMed Web of Science ®Google Scholar
• Curtis NJ, van Heyningen C, Turner JJ. Irreversible nephrotoxicity from demeclocycline in the treatment of hyponatremia. Age Ageing. 2002;31:151–152.
   PubMed Web of Science ®Google Scholar
• Demeclocycline SPC. [cited 2018 Apr 2]. Available from: https://www.google.gr/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0ahUKEwjs__n1oZvaAhXJMewKHRbgCZAQFggnMAA&url=https%3A%2F%2Fwww.medicines.org.uk%2Femc%2Fproduct%2F499&usg=AOvVaw0_odtS5OsoPdn5rLeVyt75
   Google Scholar
• Sherlock M, Thompson CJ. The syndrome of inappropriate antidiuretic hormone: current and future management options. Eur J Endocrinol. 2010;162(Suppl 1):S13–S18.
   PubMedGoogle Scholar
• Soudan K, Qunibi W. Severe hypernatremia following treatment of the syndrome of inappropriate antidiuretic hormone secretion. Am J Med Sci. 2012;343:507–509.
   PubMed Web of Science ®Google Scholar
• Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis. 1987;10:329–345.
   PubMed Web of Science ®Google Scholar
• Bedford JJ, Weggery S, Ellis G, et al. Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride. Clin J Am Soc Nephrol. 2008;3:1324–1331.
   PubMed Web of Science ®Google Scholar
• Stone KA. Lithium-induced nephrogenic diabetes insipidus. J Am Board Fam Pract. 1999;12:43–47.
   PubMedGoogle Scholar
• Markowitz GS, Radhakrishnan J, Kambham N, et al. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol. 2000;11:1439–1448.
   PubMed Web of Science ®Google Scholar
• Bejot Y, Depierre P, Osseby GV, et al. Central pontine and extra-pontine myelinolysis: a complication of lithium toxicity in a pregnant woman. Clin Neurol Neurosurg. 2008;110:852–854.
   PubMed Web of Science ®Google Scholar
• Corona G, Giuliani C, Verbalis JG, et al. Hyponatremia improvement is associated with a reduced risk of mortality: evidence from a meta-analysis. PLoS One. 2015;10:e0124105.
   PubMed Web of Science ®Google Scholar
• Alskaf E, Tridente A, Al-Mohammad A. Tolvaptan for heart failure, systematic review and meta-analysis of trials. J Cardiovasc Pharmacol. 2016;68:196–203.
   PubMed Web of Science ®Google Scholar
• Yang CJ, Yang J, Yang J, et al. Arginine vasopressin antagonist tolvaptan in the treatment of heart failure: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015;8:22117–22128.
   PubMedGoogle Scholar
• Xiong B, Huang Y, Tan J, et al. The short-term and long-term effects of tolvaptan in patients with heart failure: a meta-analysis of randomized controlled trials. Heart Fail Rev. 2015;20:633–642.
   PubMed Web of Science ®Google Scholar